Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Once-Weekly shot tame type 2 diabetes blood sugar?

NCT ID NCT07796477

Disease control Sponsor: CSPC Ouyi Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 01, 2026 · Last updated Sep 02, 2026 · Updated 1 time

Summary

This Phase 2 trial tests an investigational once-weekly injection called SYH2069 in adults with type 2 diabetes whose blood sugar is not well controlled by diet, exercise, or metformin alone. Researchers compare several doses of SYH2069 against a placebo and an existing diabetes medication to see how well it lowers HbA1c, a key blood sugar marker, over 28 weeks. The study enrolls about 240 participants and also tracks safety, side effects, and how the drug behaves in the body.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
SYH2069 injection, a weekly injectable drug being tested to improve blood sugar control
What this could lead to
If it works, SYH2069 could offer a new once-weekly option to help people with type 2 diabetes manage their blood sugar more effectively.
What could go wrong
This is an early Phase 2 study, so the drug may not prove more effective than existing treatments or may cause unexpected side effects. Results will need confirmation in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Male or female participants, 18-75 years of age. * 2\. Confirmed as T2DM for at least 12 weeks. * 3\. Body Mass Index (BMI): 22 kg/m\^2 ≤ BMI ≤ 40 kg/m\^2. * 4\. Treated with lifestyle intervention and stable treatment with metformin at least 8 weeks prior to screening. * 5\. HbA1c 7.5-10.5% (both inclusive) at screening visit. * 6\. Able to understand the protocol, and voluntarily signed informed consent. Exclusion Criteria: * 1\. Type 1 diabetes or other specific types of diabetes. * 2\. Allergy to any active ingredient or any excipient of the investigational product, or presence of severe allergic diseases at screening. * 3\. Weight change \>5% within 1 month before screening. * 4\. History of a level 3 hypoglycemic episode within 6 months prior to screening. * 5\. Acute complications of diabetes occurred within 6 months prior to screening. * 6\. History of severe chronic diabetic complications within 6 months prior to screening, or have non-proliferative diabetic retinopathy that requires treatment during the study. * 7\. History of acute or chronic pancreatitis. * 8\. History of acute cardiovascular and cerebrovascular within 6 months prior to screening. * 9\. History of malignancy of any organ system within 5 years prior to screening, excluding cured basal cell carcinoma and carcinoma in situ. * 10\. History or family history of medullary thyroid carcinoma (MTC), thyroid C-cell hyperplasia, or multiple endocrine neoplasia type 2 (MEN2). * 11\. History of major surgery or suffered blood loss of more than 400 mL within 3 months prior to screening. * 12\. Pregnant or lactating woman. * 13\. Other conditions judged by the investigator to be unsuitable for participation in this trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T2DM (type 2 diabetes mellitus) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

T2DM (type 2 diabetes mellitus)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.